Does the media prefer VNDA or CRON?

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 2 articles in the media. Cronos Group's average media sentiment score of 1.89 beat Vanda Pharmaceuticals' score of 1.61 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer VNDA or CALT?

Vanda Pharmaceuticals presently has a consensus target price of $13.70, suggesting a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor PCRX or VNDA?

In the previous week, Pacira BioSciences had 8 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 10 mentions for Pacira BioSciences and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Pacira BioSciences' score of 1.01 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, VNDA or IVA?

Vanda Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vanda Pharmaceuticals $215.72M 1.43 -$220.47M -$4.63 N/A Inventiva $4.48M 186.26 -$400.67M N/A N/A

Does the media favor VNDA or IVA?

In the previous week, Inventiva had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Inventiva and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Inventiva's score of 0.86 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Amphastar Pharmaceuticals' score of 1.05 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Vanda Pharmaceuticals (VNDA) Competitors

$5.09 +0.05 (+0.99%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.03 (+0.49%)

As of 09/11/2026 07:30 PM Eastern

Compare

VNDA vs. CRON, CALT, PCRX, IVA, and AMPH

Should you buy Vanda Pharmaceuticals stock or one of its competitors? Vanda Pharmaceuticals's main competitors and comparable companies include Cronos Group (CRON), Calliditas Therapeutics AB (publ) (CALT), Pacira BioSciences (PCRX), Inventiva (IVA), and Amphastar Pharmaceuticals (AMPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vanda Pharmaceuticals compare to Cronos Group?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Cronos Group has a net margin of 39.08% compared to Vanda Pharmaceuticals' net margin of -127.41%. Cronos Group's return on equity of 4.85% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Cronos Group	39.08%	4.85%	4.62%

Cronos Group has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.43	-$220.47M	-$4.63	N/A
Cronos Group	$146.59M	7.89	-$9.45M	$0.20	15.70

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vanda Pharmaceuticals presently has a consensus price target of $13.70, indicating a potential upside of 169.16%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 26.75%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vanda Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 2 articles in the media. Cronos Group's average media sentiment score of 1.89 beat Vanda Pharmaceuticals' score of 1.61 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Cronos Group beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Vanda Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Vanda Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.43	-$220.47M	-$4.63	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Vanda Pharmaceuticals presently has a consensus target price of $13.70, suggesting a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Vanda Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Vanda Pharmaceuticals	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Summary

Vanda Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, Pacira BioSciences had 8 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 10 mentions for Pacira BioSciences and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Pacira BioSciences' score of 1.01 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pacira BioSciences has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.35	72.46
Vanda Pharmaceuticals	$215.72M	1.43	-$220.47M	-$4.63	N/A

Pacira BioSciences has a net margin of 1.96% compared to Vanda Pharmaceuticals' net margin of -127.41%. Pacira BioSciences' return on equity of 9.68% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Pacira BioSciences has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pacira BioSciences currently has a consensus price target of $29.83, suggesting a potential upside of 17.64%. Vanda Pharmaceuticals has a consensus price target of $13.70, suggesting a potential upside of 169.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Pacira BioSciences beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Inventiva?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Inventiva had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Inventiva and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Inventiva's score of 0.86 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

Inventiva has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Inventiva's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Inventiva	N/A	N/A	N/A

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 169.16%. Inventiva has a consensus price target of $15.38, indicating a potential upside of 282.46%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Vanda Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.43	-$220.47M	-$4.63	N/A
Inventiva	$4.48M	186.26	-$400.67M	N/A	N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Inventiva beats Vanda Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Amphastar Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Vanda Pharmaceuticals' net margin of -127.41%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Amphastar Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.43	-$220.47M	-$4.63	N/A
Amphastar Pharmaceuticals	$719.89M	1.41	$98.09M	$1.69	14.07

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 169.16%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential downside of 5.38%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vanda Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Amphastar Pharmaceuticals' score of 1.05 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$307.76M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-1.10	799.75	275.24	25.29
Price / Sales	1.43	763.36	656.02	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	0.92	10.39	10.33	6.20
Net Income	-$220.47M	$2.85B	$3.50B	$358.50M
7 Day Performance	-6.26%	-3.61%	-3.32%	-2.35%
1 Month Performance	-1.93%	0.86%	-0.41%	-2.77%
1 Year Performance	12.86%	3.47%	19.21%	7.63%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	3.0239 of 5 stars	$5.09 +1.0%	$13.70 +169.2%	+10.7%	$307.76M	$215.72M	N/A	290
CRON Cronos Group	1.6746 of 5 stars	$3.26 flat	$2.30 -29.4%	+21.7%	$1.20B	$146.59M	16.30	450	Positive News Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
PCRX Pacira BioSciences	3.6657 of 5 stars	$26.35 flat	$30.20 +14.6%	-6.2%	$1.05B	$726.41M	75.29	720	News Coverage Positive News Analyst Forecast
IVA Inventiva	2.2758 of 5 stars	$4.78 flat	$15.38 +221.7%	-30.3%	$992.85M	$5.07M	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. CRON, CALT, PCRX, IVA, and AMPH

How does Vanda Pharmaceuticals compare to Cronos Group?

Summary

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Vanda Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Vanda Pharmaceuticals compare to Inventiva?

Summary

How does Vanda Pharmaceuticals compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. CRON, CALT, PCRX, IVA, and AMPH

How does Vanda Pharmaceuticals compare to Cronos Group?

Is VNDA or CRON more profitable?

Which has higher valuation and earnings, VNDA or CRON?

Which has more volatility and risk, VNDA or CRON?

Do insiders & institutionals have more ownership in VNDA or CRON?

Do analysts rate VNDA or CRON?

Does the media prefer VNDA or CRON?

Summary

How does Vanda Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Is VNDA or CALT more profitable?

Which has more volatility and risk, VNDA or CALT?

Which has stronger valuation and earnings, VNDA or CALT?

Do analysts prefer VNDA or CALT?

Do institutionals and insiders have more ownership in VNDA or CALT?

Does the media favor VNDA or CALT?

Summary

How does Vanda Pharmaceuticals compare to Pacira BioSciences?

Does the media favor PCRX or VNDA?

Which has better earnings & valuation, PCRX or VNDA?

Is PCRX or VNDA more profitable?

Which has more risk & volatility, PCRX or VNDA?

Do insiders and institutionals have more ownership in PCRX or VNDA?

Do analysts prefer PCRX or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Inventiva?

Does the media favor VNDA or IVA?

Which has more risk & volatility, VNDA or IVA?

Is VNDA or IVA more profitable?

Do analysts recommend VNDA or IVA?

Which has higher valuation & earnings, VNDA or IVA?

Do institutionals and insiders hold more shares of VNDA or IVA?

Summary

How does Vanda Pharmaceuticals compare to Amphastar Pharmaceuticals?

Is VNDA or AMPH more profitable?

Which has higher earnings and valuation, VNDA or AMPH?

Do insiders & institutionals have more ownership in VNDA or AMPH?

Do analysts rate VNDA or AMPH?

Which has more risk & volatility, VNDA or AMPH?

Does the media prefer VNDA or AMPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools